Skip to main content
SpringerLink
Log in

Systemic lupus erythematosus and lupus nephritis

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Drug sales for SLE in the seven major markets in terms of market value and volume in 2012 and 2022 (estimated).

References

  1. Koutsokeras, T. & Healy, T. PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis — Global Drug Forecast and Market Analysis to 2022 (GlobalData, 2013).

    Google Scholar 

  2. Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14, S4 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK

    Toli Koutsokeras

  2. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK

    Tina Healy

Authors
  1. Toli Koutsokeras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tina Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Toli Koutsokeras or Tina Healy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutsokeras, T., Healy, T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 13, 173–174 (2014). https://doi.org/10.1038/nrd4227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4227

  • Springer Nature Limited

This article is cited by

Search

Navigation